0000950103-25-009025.txt : 20250721 0000950103-25-009025.hdr.sgml : 20250721 20250721074530 ACCESSION NUMBER: 0000950103-25-009025 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250721 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250721 DATE AS OF CHANGE: 20250721 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001723128 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38485 FILM NUMBER: 251135731 BUSINESS ADDRESS: BUSINESS PHONE: (908) 947-3120 MAIL ADDRESS: STREET 1: 400 CROSSING BOULEVARD STREET 2: 3RD FLOOR CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Atlas Holdings, Inc. DATE OF NAME CHANGE: 20171117 8-K 1 dp231799_8k.htm FORM 8-K
false 0001723128 0001723128 2025-07-21 2025-07-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): July 21, 2025

 

AMNEAL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38485   93-4225266

(State or other jurisdiction

of incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

400 Crossing Blvd

Bridgewater, NJ 08807

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (908) 947-3120

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Common Stock, par value $0.01 per share   AMRX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01 Other Events.

 

On July 21, 2025, Amneal Pharmaceuticals, Inc. (the “Company”) announced that its subsidiary, Amneal Pharmaceuticals LLC (the “Issuer”), is seeking to borrow $1,800 million of new seven-year term B loans (the “new term B loans”) under a new term loan facility and has launched an offering of $750 million aggregate principal amount of senior secured notes due 2032 (the “notes”) in a private offering. The Issuer intends to use the net proceeds of the new term B loans and the notes to refinance its existing term B loans in full, to repay a portion of outstanding amounts borrowed under its ABL facility and to pay related fees, premiums and expenses.

 

The offering of the notes is not conditioned on entry into the new term loan facility. Further, the proposed transactions are subject to market conditions and other factors, and there can be no assurance as to whether or when these transactions may be completed, or as to the actual size or terms of the transactions.

 

The notes will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act. The offering of notes will be made only to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A under the Securities Act and to non-U.S. persons in accordance with Regulation S under the Securities Act. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Neither this Current Report on Form 8-K nor the press release attached hereto as Exhibit 99.1 constitutes an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)Exhibits.

 

The following exhibits are furnished herewith:

 

Exhibit

No.

 

Description 

99.1   Press release issued July 21, 2025.
104   The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 21, 2025         AMNEAL PHARMACEUTICALS, INC.
     
        By:  

/s/ Anastasios Konidaris 

        Name:   Anastasios Konidaris
        Title:  

Executive Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer) 

 

 EX-99.1 2 dp231799_ex9901.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032

 

July 21, 2025

 

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (“Amneal”) (Nasdaq: AMRX) announced that its subsidiary, Amneal Pharmaceuticals LLC (the “Issuer”), is seeking to borrow $1.800 billion aggregate principal amount of new seven-year term B loans (the “new term B loans”) under a new term loan facility (the “Term Loan Facility”). The Issuer has also launched an offering of $750 million aggregate principal amount of senior secured notes due 2032 (the “notes”) in a private offering.

 

The Issuer intends to use the net proceeds of the new term B loans and the notes to refinance its existing term B loans in full, to repay a portion of outstanding amounts borrowed under its ABL facility and to pay related fees, premiums and expenses. The offering of the notes is not conditioned on entry into the Term Loan Facility.

 

The notes will initially be guaranteed on a senior secured basis by the same subsidiaries of the Issuer that will guarantee the Term Loan Facility, and will not be guaranteed by Amneal. The notes will be secured on a pari passu basis by the same assets that will secure the Term Loan Facility, and will have the benefit of a first-priority lien on the collateral (other than the ABL priority collateral, which primarily consists of inventory, accounts receivable and related assets) and a second-priority lien on the ABL priority collateral. The Issuer’s obligations under its existing asset-based credit facility are secured on a first priority basis on the ABL priority collateral and a second priority basis on the collateral on which the notes and the new term B loans will have a first priority lien.  

 

The proposed transactions are subject to market conditions and other factors, and there can be no assurance as to whether or when these transactions may be completed, or as to the actual size or terms of the transactions.

 

The notes will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the

 

 

 

Securities Act. The offering of notes will be made only to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A under the Securities Act and to non-U.S. persons in accordance with Regulation S under the Securities Act.

 

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

About Amneal

 

Amneal, headquartered in Bridgewater, NJ, is a global biopharmaceutical company. Amneal makes healthy possible through the development, manufacturing and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, Amneal is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, Amneal is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets.

 

Forward Looking Statements

 

Certain statements contained in this press release, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include all statements that are not historical statements of fact, as well as those regarding the proposed issuance of new term loans and the notes offering.  Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements.

 

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Amneal. Such risks and uncertainties include, but are not limited to: our financing plans and the details thereof, including the proposed use of proceeds therefrom, the expected

 

 

 

timing of the refinancing (including the new Term Loan Facility) and our ability to close such transactions, the offering of the notes and the details thereof and the other risks and uncertainties that are described from time to time in Amneal’s filings with the Securities and Exchange Commission.

 

The reader is cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

 

Investor Relations
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com

 

 

 EX-101.SCH 3 amrx-20250721.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 amrx-20250721_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 amrx-20250721_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 image_001.gif GRAPHIC begin 644 image_001.gif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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.25.2
Cover
Jul. 21, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 21, 2025
Entity File Number 001-38485
Entity Registrant Name AMNEAL PHARMACEUTICALS, INC.
Entity Central Index Key 0001723128
Entity Tax Identification Number 93-4225266
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 400 Crossing Blvd
Entity Address, City or Town Bridgewater
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08807
City Area Code 908
Local Phone Number 947-3120
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, par value $0.01 per share
Trading Symbol AMRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://amneal.com/role/Cover Cover Cover 1 false false All Reports Book All Reports amrx-20250721.xsd amrx-20250721_lab.xml amrx-20250721_pre.xml dp231799_8k.htm http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "dp231799_8k.htm": { "nsprefix": "AMRX", "nsuri": "http://amneal.com/20250721", "dts": { "schema": { "local": [ "amrx-20250721.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "amrx-20250721_lab.xml" ] }, "presentationLink": { "local": [ "amrx-20250721_pre.xml" ] }, "inline": { "local": [ "dp231799_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://amneal.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2025-07-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "dp231799_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-07-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "dp231799_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://amneal.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0000950103-25-009025-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950103-25-009025-xbrl.zip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dp231799_8k_htm.xml IDEA: XBRL DOCUMENT 0001723128 2025-07-21 2025-07-21 iso4217:USD shares iso4217:USD shares false 0001723128 8-K 2025-07-21 AMNEAL PHARMACEUTICALS, INC. DE 001-38485 93-4225266 400 Crossing Blvd Bridgewater NJ 08807 908 947-3120 false false false false Class A Common Stock, par value $0.01 per share AMRX NASDAQ false